AstraZeneca CEO defends 'fantastic' Alexion buyout in face of $753M hit from dropped drug
AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as the drugmaker reevaluated the worth of its Alexion acquisition. The drugmaker took another charge in relation to last year’s $2 billion push into radiopharmaceuticals.
AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as the drugmaker reevaluated the worth of its Alexion acquisition. The drugmaker took another charge in relation to last year’s $2 billion push into radiopharmaceuticals.
